5 µL Minimum Volume

Viral Vector Purity

Capsid ID

High-Throughput

Ultra-Low Volume, High-Throughput Gene Therapy Quality Analysis
Aura GT™ helps you realize the promise of gene therapies, without using a lot of your viral vector sample throughout the development process. Avoid conditions and formulations that facilitate viral vector aggregates, monitor DNA leakage, and ensure product quality with just 5 µL of sample per data point. Use Fluorescence Membrane Microscopy (FMM) and Backgrounded Imaging (BMI) technology to get accurate and quantitative particle size, count, morphology, and ID info. Avoid adverse immunogenetic events that can arise due to subvisible particles (SVPs) and measure the stability of the capsid to determine the shelf-life and efficacy of your product – with just 5 µL!
Don’t let the availability of viral vector samples for formulation or quality testing limit the number and types of analytics you can perform to ensure the quality of your gene therapy. Aura GT delivers accurate and precise SVP analysis with as little as 5 µL of sample. That’s 100 times less than other SVP detecting methods!
Don’t let other particles in your sample bias your analysis. Label your gene therapy with fluorescent dyes like Thioflavin T (ThT) or SYBR™ Gold to definitively ID capsid aggregates and DNA, respectively, using FMM. Make better decisions about your product and better understand the root causes of particles in your formulation.
Screen a full 96-well particle screening assay in couple of hours, not months! Now you can assess a bunch of different formulation options, monitor the stability of different AAV serotypes, test different storage conditions, and test different lots super quick!
Want More Info?
Identify the most stable AAV serotype, formulation,
and storage conditions.
Monitor nucleic acid leakage from viral vectors that can occur under common storage conditions.